Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02837640
Recruitment Status : Unknown
Verified July 2016 by Beirut Eye Specialist Hospital.
Recruitment status was:  Recruiting
First Posted : July 19, 2016
Last Update Posted : July 19, 2016
Information provided by (Responsible Party):
Beirut Eye Specialist Hospital

Brief Summary:
The purpose of this study is to evaluate the effect of L-Dopa on the progression of retinitis pigmentosa.

Condition or disease Intervention/treatment Phase
Retinitis Pigmentosa Drug: levodopa-carbidopa Phase 2

Detailed Description:
Retinitis pigmentosa is a group of progressive hereditary diseases that diffusely affects the functioning of photoreceptors and the pigment epithelium. It may be speculated that a protective effect on the pigment epithelium, as it is supposed for L-Dopa, can slow the progression of the disease or even lead to an, at least transient, improvement of visual functions. To evaluate the effect of L-Dopa on retinitis pigmentosa progression, visual acuity, electroretinogram and visual field will be preformed regularly.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of L-Dopa on the Progression of Retinitis Pigmentosa
Study Start Date : June 2016
Estimated Primary Completion Date : June 2017
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Treatment

This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.

patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months.

Drug: levodopa-carbidopa
sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
Other Name: Sinemet 200/50

Primary Outcome Measures :
  1. Change in Electroretinogram [ Time Frame: Baseline, 1 year, 2 years, 5 years ]
    the electric response to light stimuli of the retina, in millivolt, will be measured. The electroretinogram shows a-waves (elicit information about the function of the photoreceptors) and b-waves (elicit information about other neurosensory structure of the retina)

Secondary Outcome Measures :
  1. Change in Visual Acuity [ Time Frame: Baseline, 6 months, 1 year, 2 years, 5 years ]
    Visual acuity will be measured using Snellen chart

  2. Change in Visual Field [ Time Frame: Baseline, 1 year, 2 years, 5 years ]
    Using 24-2 Humphrey Visual Field Analyzer, the progress in visual field defect will be measured, comparing mean deviation (dB) and pattern standard deviation (dB)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All confirmed cases of retinitis pigmentosa
  • VA of 20/400 or better

Exclusion Criteria:

  • Advanced stages of retinitis pigmentosa with poor best corrected visual acuity (less than 20/400)
  • co-existing eye morbidities interfering with retinitis pigmentosa (glaucoma, retinal detachment...)
  • Flat electroretinogram
  • Intolerance or counterindication to drug
  • Unability for long-term follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02837640

Layout table for location contacts
Contact: Elias F. Jarade, MD +9613549297
Contact: Beirut Eye Specialist Hospital +961 1 423111 ext 0

Layout table for location information
Beirut Eye Specialist Hospital Recruiting
Beirut, Lebanon, 116-5311
Contact: George Cherfan, MD, Prof    +961 1 423111 ext 160   
Sponsors and Collaborators
Beirut Eye Specialist Hospital
Layout table for investigator information
Principal Investigator: Elias F. Jarade, MD Beirut Eye Specialist Hospital
Layout table for additonal information
Responsible Party: Beirut Eye Specialist Hospital Identifier: NCT02837640    
Other Study ID Numbers: RP DOPA
First Posted: July 19, 2016    Key Record Dates
Last Update Posted: July 19, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Individual participant date will not be shared at the moment being, since it is not of value unless it is thoroughly analysed.
Keywords provided by Beirut Eye Specialist Hospital:
Retinitis Pigmentosa
Additional relevant MeSH terms:
Layout table for MeSH terms
Retinitis Pigmentosa
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn
Carbidopa, levodopa drug combination
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors
Adjuvants, Immunologic
Immunologic Factors
Dopamine Agonists